Trials / Completed
CompletedNCT04677530
A Study of JNJ-40411813 in Healthy Japanese Male Participants
A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose and Multiple Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-40411813 in Healthy Japanese Adult Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- Male
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) after single dose and multiple dose administrations of JNJ-40411813 in Japanese healthy adult male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-40411813 | JNJ-40411813 will be administered orally. |
| DRUG | Matching Placebo | Matching placebo will be administered orally. |
Timeline
- Start date
- 2021-01-29
- Primary completion
- 2021-05-21
- Completion
- 2021-05-21
- First posted
- 2020-12-21
- Last updated
- 2025-04-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04677530. Inclusion in this directory is not an endorsement.